Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares changing hands.
Hemispherx BioPharma Trading Down 20.0%
The stock’s fifty day moving average is $6.70 and its two-hundred day moving average is $6.70.
Hemispherx BioPharma Company Profile
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- The Biggest IPO Ever… Open to Everyday Folks
- Silver records prices are great. Monthly income is better
- Read this or regret it forever
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
